COST-EFFECTIVENESS OF APIXABAN VERSUS WARFARIN IN CHINESE PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

被引：0
|
作者：
Chan, E. [1 ]
Li, X. [1 ]
Lau, C. [1 ]
Anand, S. [1 ]
机构：
[1] Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.08.393
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV26
引用
收藏
页码：A866 / A867
页数：2
相关论文
共 50 条
  • [1] Cost-Effectiveness of Apixaban versus Warfarin in Chinese Patients with Non-Valvular Atrial Fibrillation: A Real-Life and Modelling Analyses
    Li, Xue
    Tse, Vicki C.
    Lau, Wallis C. Y.
    Cheung, Bernard M. Y.
    Lip, Gregory Y. H.
    Wong, Ian C. K.
    Chan, Esther W.
    [J]. PLOS ONE, 2016, 11 (06):
  • [2] VALIDATION OF THE APIXABAN COST-EFFECTIVENESS MODEL IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
    Kachroo, S.
    Phatak, H.
    Dorian, P.
    Kongnakorn, T.
    Lanitis, T.
    Kuznik, A.
    Mardekian, J.
    Liu, X.
    Lawrence, J.
    Lip, G. Y.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A113 - A113
  • [3] Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis
    Rognoni, Carla
    Marchetti, Monia
    Quaglini, Silvana
    Liberato, Nicola Lucio
    [J]. CLINICAL DRUG INVESTIGATION, 2014, 34 (01) : 9 - 17
  • [4] Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis
    Carla Rognoni
    Monia Marchetti
    Silvana Quaglini
    Nicola Lucio Liberato
    [J]. Clinical Drug Investigation, 2014, 34 : 9 - 17
  • [5] ESTIMATION OF THE COST-EFFECTIVENESS OF APIXABAN IN NON-VALVULAR ATRIAL FIBRILLATION IN ARGENTINA
    Giorgi, M. A.
    Caroli, C.
    Micone, P.
    Giglio, N. D.
    Aiello, E. C.
    Donato, B. M. K.
    Mould, J. F.
    Radero, G.
    Casas, M.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A666 - A666
  • [6] COST-EFFECTIVENESS OF APIXABAN COMPARED TO WARFARIN AND ASPIRIN IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION (NVAF) IN THE RUSSIAN FEDERATION
    Rudakova, A., V
    Parfenov, V. A.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A489 - A489
  • [7] Cost-effectiveness of apixaban as compared with warfarin and acetylsalicylic acid in patients with non-valvular atrial fibrillation in the Russian Federation
    Rudakova, A. V.
    Parfenov, V. A.
    [J]. RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2014, 10 (03) : 275 - 282
  • [8] COST-EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS RIVAROXABAN FOR PREVENTION OF STROKE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN SPAIN
    Canal Fontcuberta, G.
    Escolar Albaladejo, G.
    Betegon Nicolas, L.
    de Salas-Cansado, M.
    Rubio-Rodriguez, D.
    Rubio-Terres, G.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A523 - A523
  • [9] COST-EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS EDOXABAN FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION SPANISH PATIENTS
    de Andres-Nogales, F.
    Oyaguez, I
    Suarez, C.
    Lopez-Sendon, J. L.
    Gonzalez-Juanatey, J. R.
    Suarez, J.
    Polanco, C.
    [J]. VALUE IN HEALTH, 2018, 21 : S106 - S106
  • [10] COST-EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS EDOXABAN FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION PORTUGUESE PATIENTS
    de Andres-Nogales, F.
    Gay-Pobes, P. R.
    Ines, M.
    Polanco Sanchez, C.
    Alves, D.
    Oyaguez, I
    [J]. VALUE IN HEALTH, 2019, 22 : S549 - S550
12345